西亚试剂优势供应上万种化学试剂产品,欢迎各位新老客户咨询、选购!

登录

¥0.00

联系方式:400-990-3999 / 邮箱:sales@xiyashiji.com

西亚试剂 —— 品质可靠,值得信赖

西亚试剂:Human prostate cancer metastases target the hematopoietic s

Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow
Yusuke Shiozawa1, Elisabeth A. Pedersen1, Aaron M. Havens1,2, Younghun Jung1, Anjali Mishra1, Jeena Joseph1, Jin Koo Kim1, Lalit R. Patel3, Chi Ying3, Anne M. Ziegler1, Michael J. Pienta1, Junhui Song4, Jingcheng Wang1, Robert D. Loberg3, Paul H. Krebsbach4, Kenneth J. Pienta3 and Russell S. Taichman1

1Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, Michigan, USA.
2Harvard School of Dental Medicine, Boston, Massachusetts, USA.
3Department of Urology and Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
4Department of Biologic and Materials Sciences, University of Michigan School of Dentistry, Ann Arbor, Michigan, USA.

HSC homing, quiescence, and self-renewal depend on the bone marrow HSC niche. A large proportion of solid tumor metastases are bone metastases, known to usurp HSC homing pathways to establish footholds in the bone marrow. However, it is not clear whether tumors target the HSC niche during metastasis. Here we have shown in a mouse model of metastasis that human prostate cancer (PCa) cells directly compete with HSCs for occupancy of the mouse HSC niche. Importantly, increasing the niche size promoted metastasis, whereas decreasing the niche size compromised dissemination. Furthermore, disseminated PCa cells could be mobilized out of the niche and back into the circulation using HSC mobilization protocols. Finally, once in the niche, tumor cells reduced HSC numbers by driving their terminal differentiation. These data provide what we believe to be the first evidence that the HSC niche serves as a direct target for PCa during dissemination and plays a central role in bone metastases. Our work may lead to better understanding of the molecular events involved in bone metastases and new therapeutic avenues for an incurable disease.